Study of three drugs for follicular lymphoma
Treatments studied
This trial tests a combination of three medications (acalabrutinib, lenalidomide, and rituximab) for people with a type of slow-growing lymphoma called follicular lymphoma. The goal is to see if this combination can control the disease and possibly lead to remission.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have follicular lymphoma that has not been treated before.
- Your lymphoma is at stage III or IV.
- You have at least one tumor that is 2 cm or larger.
- You have enough blood cells (white cells, platelets, and red cells) and your liver and kidney functions are okay.
- You are willing to practice strict birth control during and after the study.
- You have not had certain past medical conditions like other cancers, heart problems, or blood clots.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of three targeted drugs (zanubrutinib, rituximab, and venetoclax) for people with untreated follicular lymphoma. The goal is to see if this combination works better than standard treatments and has manageable side effects.
This trial tests two antibody medications, tafasitamab and rituximab, as the first treatment for newly diagnosed follicular lymphoma. The goal is to see if this combination can effectively control the lymphoma and potentially reduce the need for more intensive therapies.
This trial tests a combination of two medications (obinutuzumab and CC-99282) for people with a type of lymphoma called follicular lymphoma that has not been treated before and is considered high-burden (meaning it is widespread or growing quickly). The goal is to see if this combination helps control the cancer.
This trial tests a combination of three drugs for people with previously untreated follicular lymphoma. The goal is to see if this combination helps control the lymphoma better.
This trial tests a combination of three drugs (orelabrutinib, tafasitamab, and lenalidomide) for people newly diagnosed with follicular lymphoma. The goal is to see if this combination can shrink or control the cancer and improve outcomes.
This trial tests a combination of three drugs (zanubrutinib, obinutuzumab, and lenalidomide) as a first treatment for follicular lymphoma. The goal is to see if this triple therapy works safely and effectively.
Hear when a new Ann Arbor Stage III Grade 1 Follicular Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.